Brand names: Natrecor®
Nesiritide, BNP injection
What is nesiritide, BNP injection?
NESIRITIDE, BNP (Natrecor®) is a type of vasodilator which is given into the veins. This drug relaxes blood vessels, increasing the blood and oxygen supply to your heart. Nesiritide infusions are used to help treat severely worsened congestive heart failure. The medicine may help to improve your breathing and other symptoms. Generic nesiritide injections are available.What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:How should I use this medicine?
Nesiritide is for infusion into a vein. It will be given to you by a health-care professional in a hospital or clinic setting.What if I miss a dose?
This does not apply.What drug(s) may interact with nesiritide injection?
anesthetics used in surgeryWhat should I watch for while taking nesiritide injection?
You will be closely monitored by a health care professional while you receive the nesiritide infusion. Your blood pressure, heart function, and breathing will be monitored for signs of improvement in the heart failure.What side effects may I notice from receiving nesiritide injection?
Side effects that you should report to your prescriber or health care professional as soon as possible:Where can I keep my medicine?
This does not apply. You will not be given nesiritide to use at home. This drug is usually given only in a hospital or clinic setting.Last updated: 7/1/2002
Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | IV only |
| Identifiers | |
| CAS number | 124584-08-3 |
| ATC code | C01DX19 |
| PubChem | CID 16134381 |
| DrugBank | DB04899 |
| UNII | P7WI8UL647 |
| ChEMBL | CHEMBL1201668 |
| Chemical data | |
| Formula | C143H244N50O42S4 |
| Mol. mass | 3464 gm/mol |
| |
|
Nesiritide (Natrecor) is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation.
Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure. It received FDA approval for this purpose in 2001 after initial non-approval. In July 2011 the results of the largest study so far for nesiritide was published in The New England Journal of Medicine (NEJM); it showed that nesiritide was not associated with a change in mortality or re-hospitalizations.[1]
|
Contents
|
Nesiritide is only administered intravenously, usually by bolus, followed by IV infusion. For most adults and the elderly, a normal dosage is 2 micrograms/kilogram followed by a continuous IV infusion of 0.01 mcg/kg/minute. This may be increased every three hours for a maximum of 0.03 mcg/kg/min.
Common side effects include:
More rare side effects include:
Science or Fiction: Use of Nesiritide as a First-Line Agent? John A. Noviasky, Pharm.D., Michael Kelberman, M.D., Karen M. Whalen, B.S., Roy Guharoy, Pharm.D., William Darko, Pharm.D.[1]
|
||||||||||||||||
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)